The prescription take up plus payment terms will result in most of the recent pharma sales living outside of the q3 report. Hopefully the action and revenue pipeline will have market appeal as I doubt the cold hard revenue will
The prescription take up plus payment terms will result in most...
-
- There are more pages in this discussion • 276 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $15.97M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 36.5¢ | 32.5¢ | $8.486K | 24.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 3333 | 1 |
View Market Depth
| Last trade - 15.46pm 03/09/2024 (20 minute delay) ? |
| RGT (ASX) Chart |